logo-loader
viewScancell Holdings PLC

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Scancell Holdings PLC - Scancell to begin UK arm of phase II skin cancer trial ‘immediately’
SCIB1 has already shown itself to be safe and, more importantly, beneficial

Scancell Holdings PLC (LON:SCLP) is to begin the UK arm of the phase II trial of its flagship skin cancer treatment immediately.

The trial is testing the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s blockbuster checkpoint inhibitor Keytruda.

UK regulators gave the study the green light back in April, but it is yet to get underway because of delays in receiving approval from the US Food and Drug Administration, which was needed before recruitment could start.

WATCH: Scancell back in the clinic with a phase II trial of its flagship skin cancer treatment

Last October, the FDA requested more information around TriGrid – a delivery system developed by a third party – before deciding whether to grant SCIB1 investigational new drug (IND) status.

Despite “extensive dialogue” between the two parties, a resolution has yet to be agreed, so Scancell has temporarily withdrawn its US IND application in order to allow the UK arm of the trial to proceed “immediately”.

Bosses will re-submit the application at a “later date” after US officials have had more time to look at the TriGrid 2.0 delivery device and make sure they are happy with it.

“We are pleased to be able to advance our SCIB1 Phase 2 trial in the UK as we believe that SCIB1 administration with an immune checkpoint inhibitor such as pembrolizumab has the potential to offer greater efficacy than when either agent is used alone,” said chief executive Cliff Holloway.

“Whilst it is disappointing that discussions in the US have taken longer than anticipated, we will continue our dialogue with both Ichor and the Agency, and plan to resubmit the IND as soon as possible.”

Shares were down 3.5% to 7p in early deals on Monday.

Quick facts: Scancell Holdings PLC

Price: 5.065 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read